Table 2.
HCC features and liver parenchyma morphology at MRI by majority consensus in patients with NAFLD-associated HCC (n = 48) by non-cirrhotic (n = 26) and cirrhotic (n = 22) liver morphology
| HCC imaging features |
Main cohort (n = 48) |
Non-cirrhotic morphology (n = 26) |
Cirrhotic morphology (n = 22) |
p-value |
| APHE | 45 (93.4) | 24 (92.3) | 21 (95.4) | 1.0 |
| PVWO | 30 (62.5) | 15 (57.7) | 15 (68.1) | 0.56 |
| DPWO | 38 (79.2) | 19 (73.1) | 19 (86.3) | 0.31 |
| Enhancing “Capsule” | 34 (70.8) | 21 (80.1) | 13 (59.1) | 0.12 |
| T2W hyperintense | 40 (83.3) | 26 (100) | 14 (63.4) | <0.001 |
| T1W hypointense | 28 (58.3) | 23 (88.5) | 5 (22.7) | <0.001 |
| DWI hyperintense | *28 (87.5) | **19 (100) | ***9 (69.2) | 0.019 |
APHE, arterial phase hyperenhancement; DPWO, delayed phase washout; DWI, diffusion weighted imaging; T1W, T1 weighted; T2W, T2 weighted.
DWI available for *32/48, **19/26 and *** 13/22. p-value for non-cirrhotic group versus cirrhotic group; categorical data analyzed using Fisher’s exact test.